Trial intelligence / Profile preview

Cetuximab with Concomitant-boost Radiotherapy in Japanese Locally Advanced SCCHN

NCT00865098Phase 2Completed

Sponsor
Merck KGaA
Start
Mar 2009
Primary completion
Jun 2010
Modality
Monoclonal Antibodies
Countries
1
01

Overview

A Phase 2 trial of KL-140 in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Merck KGaA. Started Mar 2009; status: completed.

02

Drugs

KL-140
03

Conditions

squamous cell carcinoma of the head and neck (HNSCC)

Beyond the preview

Go deeper on NCT00865098.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00865098.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call